DrugDashboards

Gentamicin

Gentamicin · GENTAMICIN SULFATE 10 mg/mL · Injection, Solution · Intramuscular; Intravenous · Eugia US LLC

NDC 55150-0401-25 · 25 VIAL, SINGLE-DOSE in 1 CARTON / 2 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. One of its named manufacturing plants, Eugia Pharma Specialities Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$90.00
Reported to Texas DSHS · 2026 annual filing · Eugia Us Llc

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 80 MG
$1.925
HCPCS J1580 · Jul 1, 2026 quarter · typically ASP + 6%

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for gentamicin (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA215236
TE code
Approval date
Jan 8, 2024
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · OngoingMay 29, 2025
    Eugia US LLCFailed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Manufacturers of Gentamicin (Injection, Solution)

LabelerStrengthFirst seenLast seen
Eugia US LLCGENTAMICIN SULFATE 40 mg/mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCGENTAMICIN SULFATE 10 mg/mLJul 15, 2026Sep 3, 2026
Eugia US LLCGENTAMICIN SULFATE 10 mg/mLJul 15, 2026Sep 2, 2026
HF Acquisition Co LLC, DBA HealthFirstGENTAMICIN SULFATE 40 mg/mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.GENTAMICIN SULFATE 40 mg/mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Gentamicin — NDC 55150-0401-25," retrieved September 3, 2026, https://drugdashboards.com/drug/55150040125.

Free to cite with attribution — see how the data is put together.